Outcomes for patients with synchronous and metachronous primary lung cancer after diagnosis of head and neck cancer

Head Neck. 2017 Aug;39(8):1544-1549. doi: 10.1002/hed.24751. Epub 2017 Jun 7.

Abstract

Background: Not-infrequently patients with head and neck cancer are also diagnosed with synchronous lung cancer or metachronous primary lung cancer, which complicates the treatment decisions and prognosis.

Methods: Patients were identified from a database of patients with head and neck cancer with second primary non-small cell lung cancer (NSCLC).

Results: Thirty-four eligible patients (15 with synchronous lung cancer and 19 with metachronous lung cancer) were identified. Thirteen of 15 patients with synchronous lung cancer received curative intent treatment for head and neck cancer first. Six of 15 patients were in complete remission, 5 of 15 patients had died, and 4 were alive with progressive disease. Median time between 2 diagnoses was 47 months in the metachronous lung cancer group. Twelve patients had died, 3 were alive with disease, and 4 were lost to follow-up. Median survival from the time of lung cancer diagnosis was 13 months with a trend to better survival with synchronous lung cancer (15 vs 11 months; p = .11).

Conclusion: Aggressive multidisciplinary management of second primary lung malignancies in patients with head and neck cancer can result in respectable long-term disease control particularly in patients with synchronous lung cancer. © 2017 Wiley Periodicals, Inc. Head Neck 39: 1544-1549, 2017.

Keywords: head and neck cancer; metachronous primary lung cancer; nonsmall cell lung cancer (NSCLC); synchronous primary lung cancer.

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / therapy
  • Aged
  • Aged, 80 and over
  • Carcinoma, Large Cell / mortality
  • Carcinoma, Large Cell / therapy
  • Combined Modality Therapy
  • Female
  • Head and Neck Neoplasms / mortality*
  • Head and Neck Neoplasms / therapy
  • Humans
  • Lung Neoplasms / mortality*
  • Lung Neoplasms / therapy
  • Male
  • Middle Aged
  • Neoplasms, Multiple Primary / mortality*
  • Neoplasms, Multiple Primary / therapy
  • Neoplasms, Second Primary / mortality*
  • Neoplasms, Second Primary / therapy
  • Neoplasms, Squamous Cell / mortality
  • Neoplasms, Squamous Cell / therapy
  • Pneumonectomy
  • Survival Analysis